ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,00%
Bitcoin
60.860,75
0,11%
Brent Oil
82,585
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Journey Medical Corporation (DERM)

  7. Journey Medical Corporation (DERM) Notícias

DERM

Journey Medical (DERM)

Journey Medical Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:DERM
DataHoraFonteTítuloCódigoCompanhia
07/05/202409:30GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:DERMJourney Medical Corporation
01/05/202417:01GlobeNewswire Inc.Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerNASDAQ:DERMJourney Medical Corporation
25/04/202409:30GlobeNewswire Inc.Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024NASDAQ:DERMJourney Medical Corporation
21/03/202417:01GlobeNewswire Inc.Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
18/03/202409:30GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaNASDAQ:DERMJourney Medical Corporation
15/03/202409:30GlobeNewswire Inc.Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024NASDAQ:DERMJourney Medical Corporation
13/03/202409:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceNASDAQ:DERMJourney Medical Corporation
11/03/202409:30GlobeNewswire Inc.Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingNASDAQ:DERMJourney Medical Corporation
23/02/202419:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DERMJourney Medical Corporation
05/01/202410:30GlobeNewswire Inc.Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
02/01/202418:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DERMJourney Medical Corporation
02/01/202418:05GlobeNewswire Inc.Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 MillionNASDAQ:DERMJourney Medical Corporation
15/12/202318:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DERMJourney Medical Corporation
06/12/202310:00GlobeNewswire Inc.Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
07/11/202318:01GlobeNewswire Inc.Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
31/10/202309:30GlobeNewswire Inc.Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:DERMJourney Medical Corporation
20/10/202309:30GlobeNewswire Inc.Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)NASDAQ:DERMJourney Medical Corporation
06/09/202309:00GlobeNewswire Inc.Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian NationsNASDAQ:DERMJourney Medical Corporation
14/08/202317:01GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
10/08/202317:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DERMJourney Medical Corporation
08/08/202317:01GlobeNewswire Inc.Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
02/08/202317:01GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023NASDAQ:DERMJourney Medical Corporation
19/07/202309:30GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023NASDAQ:DERMJourney Medical Corporation
11/07/202309:30GlobeNewswire Inc.Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in AdultsNASDAQ:DERMJourney Medical Corporation
03/07/202309:00GlobeNewswire Inc.Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of JulyNASDAQ:DERMJourney Medical Corporation
23/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DERMJourney Medical Corporation
13/06/202309:30GlobeNewswire Inc.Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsNASDAQ:DERMJourney Medical Corporation
22/05/202317:01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
19/05/202317:01GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023NASDAQ:DERMJourney Medical Corporation
15/05/202317:01GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:DERM

Seu Histórico Recente

COIN
TOPCUSD
TopChain
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados